A Cornell researcher, who is a leader in developing a new type of gene editing CRISPR system, and colleagues have used the new method for the first time in human cells – a major advance in the field.
The new system, called CRISPR-Cas3, can efficiently erase long stretches of DNA from a targeted site in the human genome, a capability not easily attainable in more traditional CRISPR-Cas9 systems. Though robust applications may be well in the future, the new system has the potential to seek out and erase such ectopic viruses as herpes simplex, Epstein-Barr, and hepatitis B, each of which is a major threat to public health.
“My lab spent the past ten years figuring out how CRISPR-Cas3 works. I am thrilled that my colleagues and I finally demonstrated its genome editing activity in human cells,” said Ailong Ke, professor of molecular biology and genetics and a corresponding author of a paper published April 8 in the journal Molecular Cell. “Our tools can be made to target these viruses very specifically and then erase them very efficiently. In theory, it could provide a cure for these viral diseases.”
The CRISPR-Cas3 technology also allows researchers to scan through the genome and detect non-coding genetic elements, which make up 98 percent of our genome but have not been well characterized. These elements act as regulators that control the expression of proteins in coding genes, and they’ve been found to be pivotal for cell differentiation and sex determination.
CRISPR-Cas3 could be used to efficiently screen for non-coding genetic elements and erase long sequences of DNA. Once erased, researchers may look to see what functions are missing in an organism, to determine the role of that genetic element.
Yan Zhang, assistant professor of biological chemistry at the University of Michigan, is also a corresponding author of the paper. First authors are Adam Dolan, a graduate student in Ke’s lab, and Zhonggang Hou, a research lab specialist in Zhang’s lab.
CRISPR-Cas9 systems use a bacterial RNA as a guide pairs with and recognizes a sequence of DNA. When a match is found, the guide RNA directs CRISPR-associated (Cas) proteins to that precise string of DNA. Once located, the Cas9 protein snips the target DNA at just the right place. CRISPR-Cas3 uses the same mechanism to locate a specific sequence of DNA, however, instead of snipping the DNA in half, its nuclease erases DNA continuously, for up to 100 kilobases.
For the first time, Ke, Zhang and colleagues successfully deleted sequences of up to 100 kilobases of targeted DNA in human embryonic stem cells and in another cell type called HAP1.
While CRISPR-Cas3 holds the potential for a more impactful genome-editing tool than CRISPR-Cas9, the researchers are working to control how long a section they delete. “We can’t quite define the deletion boundaries precisely, and that is a shortcoming when it comes to therapeutics,” Ke said.
The Latest on: CRISPR-Cas3
via Google News
The Latest on: CRISPR-Cas3
- $20M Investment Bolsters Locus Biosciences’ CRISPR-Cas Innovationon July 5, 2019 at 3:19 pm
In February, Locus Biosciences, Inc. entered an exclusive collaboration and licensing agreement with Janssen Pharmaceuticals, Inc. focused on developing and manufacturing CRISPR-Cas3-enhanced ...
- The New CRISPR Tool That Could ‘Delete’ Disease From Our DNAon May 30, 2019 at 12:54 pm
Elements is more than just a science show. It’s your science-loving best friend, tasked with keeping you updated and interested on all the compelling, innovative and groundbreaking science happening ...
- CRISPR-Cas3 innovation holds promise for disease cures, advancing scienceon April 11, 2019 at 1:50 pm
ITHACA, N.Y. - A Cornell researcher, who is a leader in developing a new type of gene editing CRISPR system, and colleagues have used the new method for the first time in human cells - a major advance ...
- CRISPR-Cas3 innovation holds promise for disease cures, advancing scienceon April 10, 2019 at 5:00 pm
Scientists have used a new type of gene editing CRISPR system for the first time in human cells - a major advance in the field. A Cornell researcher, who is a leader in developing a new type of gene ...
- CRISPR upgraded from ‘scissors’ to ‘shredder’on April 10, 2019 at 2:50 am
A novel CRISPR-Cas3 based tool acts more like a ‘shredder’, as opposed to the single-sequence targeting ‘scissors’, with the ability to wipe out long stretches of human DNA. An international ...
- Locus and Janssen Ink Potential $818 Million Dealon January 3, 2019 at 10:00 am
The companies will work to develop precision antibacterial therapies based on CRISPR-Cas3-enhanced bacteriophage. Under the terms of the deal, Janssen is paying Locus $20 million up front. Locus will ...
- Locus Biosciences Enters a Collaboration and License Agreement with Johnson & Johnson Innovation to develop CRISPR-Cas3 Bacteriophage Therapeuticson January 3, 2019 at 6:14 am
RESEARCH TRIANGLE PARK, N.C., Jan. 3, 2019 /PRNewswire/ -- Locus Biosciences Inc., a biotechnology company developing precision antibacterial therapies, announced today that it has entered into an ...
- J&J takes stake in Locus’ CRISPR-based ‘Pac-Man’ antimicrobialson January 3, 2019 at 6:07 am
It’s using another pathway—CRISPR-Cas3—to tackle the issue of rising resistance to the current antimicrobial armamentarium at a time when many companies have backed away from researching new drugs.
- Locus Bio Raises $19M for CRISPR-Cas3 Antimicrobial “Smart Bombs”on November 13, 2018 at 4:00 pm
A growing number of companies are using CRISPR technology to try and develop more precise treatments for a wide range of diseases, and Locus Biosciences is joining the mix, embracing the platform to ...
- Locus Biosciences Secures $5m Convertible Note for CRISPR-Cas3 Antimicrobialson July 10, 2017 at 6:32 am
RESEARCH TRIANGLE PARK, N.C., July 10, 2017 /PRNewswire/ -- Locus Biosciences Inc. today announced the closing of a $5m Convertible Note to support the development of CRISPR-Cas3 antimicrobial ...
via Bing News